研究单位：[1]Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,[2]The First Affiliated Hospital of Soochow University[3]Shanghai Ming Ju Biotechnology Co., Ltd.[4]Sun Yat-sen University Cancer Hospital,Guangzhou,Guangdong,China[5]Henan Cancer Hospital,Zhengzhou,Henan,China[6]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China[7]Hunan Cancer Hospital,Changsha,Hunan,China[8]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,215006[9]Shandong Cancer Hospital,Jinan,Shandong,China[10]Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,,Shanghai,Shanghai,China,200025[11]Institute of Hematology&Hospital of Blood Disease CAMS,Tianjin,Tianjin,China,300000[12]Tianjin Cancer Hospital,Tianjin,Tianjin,China[13]The First Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,China[14]Beijing Tongren Hospital,Beijing,China[15]Peking Union Medical College Hospital,Beijing,China[16]Jiangsu Provincial People's Hospital,Nanjing,China
The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are ineligible for haematopoietic stem cell transplantation.
